Expression of the Bcl-3 proto-oncogene suppresses p53 activation
- PMID: 16384933
- PMCID: PMC1356113
- DOI: 10.1101/gad.1352206
Expression of the Bcl-3 proto-oncogene suppresses p53 activation
Abstract
While Bcl-3 expression in cancer was originally thought to be limited to B-cell lymphomas with a 14;19 chromosomal translocation, more recent evidence indicates that expression of this presumptive oncoprotein is significantly more widespread in cancer. However, an oncogenic role for Bcl-3 has not been clearly identified. Experiments presented here indicate that Bcl-3 is inducible by DNA damage and is required for the induction of Hdm2 gene expression and the suppression of persistent p53 activity. Furthermore, constitutive expression of Bcl-3 suppresses DNA damage-induced p53 activation and inhibits p53-induced apoptosis through a mechanism that is at least partly dependent on the up-regulation of Hdm2. The results provide insight into a mechanism whereby altered expression of Bcl-3 leads to tumorigenic potential. Since Bcl-3 is required for germinal center formation, these results suggest functional similarities with the unrelated Bcl-6 oncoprotein in suppressing potential p53-dependent cell cycle arrest and apoptosis in response to somatic hypermutation and class switch recombination.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig1.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig2.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig3.gif)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig4.gif)
![Figure 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig5.gif)
![Figure 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1356113/bin/225fig6.gif)
Similar articles
-
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.Nature. 2004 Dec 2;432(7017):635-9. doi: 10.1038/nature03147. Nature. 2004. PMID: 15577913
-
Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression.Mol Cell Biol. 2005 Jul;25(14):6247-58. doi: 10.1128/MCB.25.14.6247-6258.2005. Mol Cell Biol. 2005. PMID: 15988033 Free PMC article.
-
Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells.Oncogene. 2001 Nov 29;20(55):8009-18. doi: 10.1038/sj.onc.1204981. Oncogene. 2001. PMID: 11753684
-
No PUMA, no death: implications for p53-dependent apoptosis.Cancer Cell. 2003 Oct;4(4):248-9. doi: 10.1016/s1535-6108(03)00249-6. Cancer Cell. 2003. PMID: 14585351 Review.
-
Regulation of hematopoietic stem cell integrity through p53 and its related factors.Ann N Y Acad Sci. 2016 Apr;1370(1):45-54. doi: 10.1111/nyas.12986. Epub 2015 Dec 22. Ann N Y Acad Sci. 2016. PMID: 26695737 Review.
Cited by
-
Suppression of Bcl3 Disrupts Viability of Breast Cancer Cells through Both p53-Dependent and p53-Independent Mechanisms via Loss of NF-κB Signalling.Biomedicines. 2024 Jan 10;12(1):143. doi: 10.3390/biomedicines12010143. Biomedicines. 2024. PMID: 38255248 Free PMC article.
-
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age.Mol Cancer. 2024 Jan 9;23(1):7. doi: 10.1186/s12943-023-01922-8. Mol Cancer. 2024. PMID: 38195591 Free PMC article. Review.
-
p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).Front Pharmacol. 2022 May 27;13:871583. doi: 10.3389/fphar.2022.871583. eCollection 2022. Front Pharmacol. 2022. PMID: 35721196 Free PMC article. Review.
-
Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.Breast Cancer Res. 2022 Jun 9;24(1):40. doi: 10.1186/s13058-022-01536-w. Breast Cancer Res. 2022. PMID: 35681213 Free PMC article.
-
BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination.DNA Repair (Amst). 2022 Jul;115:103331. doi: 10.1016/j.dnarep.2022.103331. Epub 2022 Apr 16. DNA Repair (Amst). 2022. PMID: 35468497 Free PMC article.
References
-
- Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. - PubMed
-
- Bond, G.L., Hu, W., and Levine, A.J. 2005. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5: 3-8. - PubMed
-
- Boulton, S.J., Gartner, A., Reboul, J., Vaglio, P., Dyson, N., Hill, D.E., and Vidal, M. 2002. Combined functional genomic maps of the C. elegans DNA damage response. Science 295: 127-131. - PubMed
-
- Bours, V., Franzoso, G., Azarenko, V., Park, S., Kanno, T., Brown, K., and Siebenlist, U. 1993. The oncoprotein Bcl-3 directly transactivates through κ B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous